ClinicalTrials.gg

Program

dupilumab

Also written as “Dupilumab”, “Dupilumab SAR231893” and “Dupilumab (SAR231893)”.

Its studies are mostly in Dermatitis, Atopic · Asthma · Eosinophilic Esophagitis · Nasal Polyps · Pulmonary Disease, Chronic Obstructive, led by 3 companies.

Furthest: phase 4, since Jul 16, 201993 company-led studies, 14 open or runningNext primary completion: Feb 7, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi529 open or runningphase 4since Jul 16, 2019Mar 9, 2011Feb 7, 2027phase 4 · NCT07905547
Regeneron Pharmaceuticals404 open or runningphase 4since Dec 17, 2019Nov 10, 2009Apr 24, 2027phase 4 · NCT06572228
Andover Eye Associates11 open or runningphase 2since Mar 2, 2020Mar 2, 2020none ahead

Also a collaborator on its studies: aimmune-therapeutics-inc and statistics-data-corporation.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 43 studies since Feb 6, 2017.

  1. May 18, 2023Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsSanofi · NCT05878093 · 63 enrolled · China
  2. Jul 28, 20233 phase 1 studiesSanofi · NCT05976386, NCT05976373, NCT05976360
  3. Aug 1, 2023Phase 4 study in Dermatitis, AtopicSanofi · NCT05983068 · 48 enrolled · United States, United Kingdom
  4. Oct 19, 2023Phase 4 study in Eosinophilic EsophagitisSanofi · NCT06101095 · 69 enrolled · United States, Brazil, Canada and more
  5. Dec 19, 2023Phase 3 study in Respiratory SoundsSanofi · NCT06191315 · 90 planned · United States, Argentina, Brazil and more
  6. Feb 27, 2024Phase 3 study in Prurigo NodularisSanofi · NCT06293053 · 18 planned · United States
  7. Aug 23, 2024Phase 4 study in AsthmaRegeneron Pharmaceuticals · NCT06572228 · 120 enrolled · United States, Canada, Denmark and more
  8. Nov 12, 20242 phase 3 studies in NeurodermatitisSanofi · NCT06687980, NCT06687967
  9. Jun 27, 2025Phase 4 study in Pulmonary Disease, Chronic ObstructiveSanofi · NCT07053423 · 218 planned · United States, Argentina, Austria and more
  10. Aug 1, 2025Phase 3 study in Eosinophilic EsophagitisRegeneron Pharmaceuticals · NCT07112378 · 20 planned · United States
  11. Sep 15, 2025Phase 4 study in Dermatitis, AtopicRegeneron Pharmaceuticals · NCT07187089
  12. May 8, 2026Phase 4 study in Pulmonary Disease, Chronic ObstructiveRegeneron Pharmaceuticals · NCT07587658 · 754 planned · United States
  13. Jun 8, 2026Phase 1 study in Healthy VolunteersSanofi · NCT07646548 · 40 enrolled · United States
  14. Oct 23, 2026Phase 4 study in Dermatitis, AtopicSanofi · NCT07905547 · 56 planned

Ahead

  1. Feb 7, 2027Primary completion: phase 4 study in Dermatitis, AtopicSanofi · NCT07905547
  2. Mar 16, 2027Primary completion: phase 4 study in AsthmaSanofi · NCT05097287
  3. Apr 24, 2027Primary completion: phase 4 study in AsthmaRegeneron Pharmaceuticals · NCT06572228
  4. Apr 29, 2027Primary completion: phase 4 study in Dermatitis, AtopicSanofi · NCT05983068

TargetBeta

IL4R →read by rule
“Interleukin-4 receptor subunit alpha antagonist”ChEMBL 37, by rule

Other programs on IL4R

ProgramCompanyFurthest phaseStudies
drotokibartJiangsu HengRui Medicinephase 38
TQH2722Sino Biopharmaceuticalphase 37
SHR-1819Jiangsu HengRui Medicinephase 35

Studies

The newest 60 of 93 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07905547Dermatitis, Atopic4Not yet recruitingSanofiFeb 7, 202756
NCT07646548Healthy Volunteers · United States1CompletedSanofiSep 30, 202640
NCT07587658Pulmonary Disease, Chronic Obstructive · United States4RecruitingRegeneron PharmaceuticalsJul 30, 2028754
NCT07187089Dermatitis, Atopic4WithdrawnRegeneron PharmaceuticalsDec 23, 20270
NCT07112378Eosinophilic Esophagitis · United States3RecruitingRegeneron PharmaceuticalsJun 19, 202820
NCT07053423Pulmonary Disease, Chronic Obstructive · United States, Argentina, Austria and more4RecruitingSanofiDec 23, 2028218
NCT06687980Neurodermatitis · United States, Argentina, Belgium and more3CompletedSanofiJun 8, 2026138
NCT06687967Neurodermatitis · United States, Argentina, Canada and more3CompletedSanofiJun 8, 2026142
NCT06572228Asthma · United States, Canada, Denmark and more4Active, not recruitingRegeneron PharmaceuticalsApr 24, 2027120
NCT06293053Prurigo Nodularis · United States3RecruitingSanofiOct 28, 202718
NCT06191315Respiratory Sounds · United States, Argentina, Brazil and more3By invitationSanofiDec 21, 202890
NCT06101095Eosinophilic Esophagitis · United States, Brazil, Canada and more4Active, not recruitingSanofiNov 5, 202569
NCT05983068Dermatitis, Atopic · United States, United Kingdom4Active, not recruitingSanofiApr 29, 202748
NCT05976386Healthy Volunteers · United States1CompletedSanofiSep 24, 2021182
NCT05976373Healthy Volunteers · United States1CompletedSanofiMar 30, 201538
NCT05976360Healthy Volunteer · United States1CompletedSanofiJan 17, 201538
NCT05878093Chronic Rhinosinusitis With Nasal Polyps · China3CompletedSanofiSep 6, 202463
NCT05831176Eosinophilic enteropathy · United States, Canada, Italy and more2Active, not recruitingRegeneron PharmaceuticalsFeb 23, 202622
NCT05731128Colitis, Ulcerative · United States, Argentina, Canada and more2Active, not recruitingSanofiMay 13, 202668
NCT05680298Dermatitis, Atopic · China4CompletedSanofiDec 22, 202334
NCT05624112Dermatitis, Atopic · China4CompletedSanofiJan 25, 202444
NCT05590585Dermatitis, Atopic · United States4CompletedRegeneron PharmaceuticalsNov 14, 2024124
NCT05526521Chronic Urticaria · United States, Canada, Japan3CompletedSanofiNov 11, 202415
NCT05263206Pruritus · United States, Argentina, Canada and more3RecruitingSanofiJun 2, 2027284
NCT05097287Asthma · United States, Belgium, Brazil and more4Active, not recruitingSanofiMar 16, 20271,339
NCT05049122Chronic Rhinosinusitis With Nasal Polyps · Japan4CompletedSanofiDec 21, 202225
NCT04998604Asthma · United States, Belgium, Canada and more4CompletedSanofiOct 16, 2024360
NCT04823130Dermatitis, Atopic · United States, Germany4CompletedSanofiJun 30, 202254
NCT04718870Dermatitis, Atopic · United States, United Kingdom4CompletedSanofiSep 7, 202241
NCT04684524Allergic Fungal Sinusitis · United States, Argentina, Canada and more3CompletedSanofiDec 14, 202462
NCT04681729Cold Urticaria · United States, Argentina, Canada and more3CompletedSanofiFeb 2, 202382
NCT04678882Dermatitis, Atopic · Japan3CompletedSanofiDec 14, 202162
NCT04678856Sinusitis · United States, Argentina, Belgium and more2CompletedSanofiNov 14, 202371
NCT04502862Asthma · United States, Argentina, Canada and more4CompletedSanofiOct 3, 2023202
NCT04456673Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3CompletedSanofiFeb 28, 2024935
NCT04447417Dermatitis, Atopic · United States, Canada4CompletedSanofiJun 17, 202152
NCT04442269Aspergillosis, Allergic Bronchopulmonary · United States, Bulgaria, France and more2CompletedRegeneron PharmaceuticalsJul 27, 202362
NCT04417894Moderate to Severe Atopic Hand and Foot Dermatitis · United States, Germany, Japan and more3CompletedRegeneron PharmaceuticalsAug 31, 2022133
NCT04400318Asthma · United States, Bulgaria, Denmark and more4CompletedSanofiJun 26, 2023109
NCT04394351Eosinophilic Esophagitis · United States, Canada3CompletedRegeneron PharmaceuticalsJun 2, 2022102
NCT04296864Atopic Keratoconjunctivitis · United States2RecruitingAndover Eye AssociatesJan 202542
NCT04206553Pemphigoid, Bullous · United States, Australia, France and more3CompletedRegeneron PharmaceuticalsJul 12, 2024106
NCT04203797Asthma · United States, France, Germany and more4CompletedRegeneron PharmaceuticalsJul 15, 202340
NCT04202679Neurodermatitis · United States, Canada, Chile and more3CompletedSanofiAug 30, 2021160
NCT04183335Neurodermatitis · United States, Argentina, China and more3CompletedSanofiNov 12, 2021151
NCT04180488Chronic Urticaria · United States, Argentina, Canada and more3CompletedSanofiAug 1, 2024397
NCT04033367Dermatitis, Atopic · United States, Australia, France and more4CompletedSanofiOct 6, 2021188
NCT03930732Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more3CompletedSanofiFeb 8, 2023939
NCT03793608Peanut Hypersensitivity · United States, Canada2CompletedRegeneron PharmaceuticalsFeb 19, 202125
NCT03912259Dermatitis, Atopic · China3CompletedSanofiFeb 14, 2020165
NCT03782532Asthma · China, India3CompletedSanofiMay 21, 2022486
NCT03736967Dermatitis, Atopic · United States, Belgium, Czechia and more2TerminatedRegeneron PharmaceuticalsMar 13, 2020206
NCT03682770Peanut Hypersensitivity · United States2CompletedRegeneron PharmaceuticalsOct 16, 2020148
NCT03633617Eosinophilic Esophagitis · United States, Australia, Belgium and more3CompletedRegeneron PharmaceuticalsSep 9, 2021321
NCT03620747Asthma · United States, Argentina, Belgium and more3CompletedSanofiFeb 18, 2022393
NCT03558997Rhinitis, Allergic · United States, Canada2CompletedRegeneron PharmaceuticalsMay 14, 2019103
NCT03560466Asthma · United States, Argentina, Australia and more3CompletedSanofiApr 1, 2025378
NCT03345914Dermatitis, Atopic · United States, Canada, Czechia and more3CompletedRegeneron PharmaceuticalsJun 20, 2019367
NCT03112577Asthma · United States, United Kingdom1CompletedRegeneron PharmaceuticalsMar 20, 201932
NCT03346434Dermatitis, Atopic · United States, Germany, Poland and more3CompletedRegeneron PharmaceuticalsJul 8, 2021202

How it is read

Names in the registry

  • “Dupilumab”, 55 entries
  • “Dupilumab SAR231893”, 13 entries
  • “dupilumab”, 10 entries
  • “Dupilumab (SAR231893)”, 5 entries
  • “REGN668”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.